Spondyloarthritis & psoriatic arthritis
Biologic disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts
Main finding · bDMARD retentionResult — go to the resultHazard ratio 1.09 95% CI 0.76–1.58Authors' conclusion
bDMARDs were similarly effective in terms of drug retention in patients with low and high joint counts.
Study context
- Population
- PsA patients with available 66/68 joint count assessments starting a first bDMARD
- Participants
- 197 vs 190
- Exposure
- First bDMARD in PsA with low vs high joint count
- Low joint count (LJC)n = 197
- High joint count (HJC)n = 190reference
- Outcome
- bDMARD retention
Methodological detailsunivariate and multivariable adjusted Cox regression
- Univariate and multivariable adjusted Cox regression
Main finding
As reported in the abstract
Hazard ratio
1.09
95% CI 0.76–1.58
P = 0.52
LJCvs HJC
HR 1.09 (95% CI 0.76–1.58); P = 0.52
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| bDMARD retention withvs without csDMARD co-therapy | 0.63 (0.47–0.85) | P < 0.002 | |
| 0.512Hazard ratio (log scale) |
Baseline differences · first bDMARD initiation
- LJC had lower enthesitis scores, less often dactylitis, less disability, better health-related quality of life and were less often on csDMARDs than HJC
Original publication
Biologic disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts. Rheumatology (Oxford). Published 7 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →